PROSCA/BLADDR 2022 | Role of systemic therapy in bladder preservation in MIBC

Aristotelis Bamias, MD, University of Athens, Athens, Greece, discusses the role of systemic therapy in the management of muscle-invasive bladder cancer (MIBC), where the addition of chemotherapy has improved outcomes when combined with radiotherapy. Dr Bamias outlines the role of novel agents such as immune checkpoint inhibitors in this setting. This interview took place at the Global Congress on Prostate and Bladder Cancer (PROSCA/BLADDR 2022) in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.